WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today recognized Egalet Ltd., a specialty pharmaceutical company focused on developing safe, effective, and tamper-resistant medications, as a Top Five Technologies To Reduce Prescription Drug Abuse honoree.
Egalet is developing a pipeline of tamper-resistant opioids that are nearing pivotal testing.
Roland Gerritsen van der Hoop, Chief Medical Officer of Egalet, received the award on behalf of the company during the National Prescription Drug Abuse Prevention Policy Consensus Meeting in Washington, DC.
"We are honored to be recognized by CLAAD for our efforts to bring to market abuse-resistant opioids," said Bob Radie, CEO and president of Egalet. "We believe our erosion-based delivery technology will help improve the safe delivery of opioids."
The Top 5 Technologies competition aims to increase public awareness of the U.S. prescription drug abuse epidemic, and to support private-sector efforts to address the problem.
Michael Barnes, spokesman for CLAAD, stated, "We are pleased to honor Egalet for its work to develop pharmaceutical products that are less susceptible to tampering and abuse."
San Diego-based Millennium Laboratories co-sponsored the Top 5 Technologies contest. Millennium provides medication monitoring, drug detection and pharmacogenetic testing services.
"We are proud to recognize Egalet for joining Millennium and CLAAD in our efforts to advance patient care and reduce prescription drug abuse," said Howard Appel, President of Millennium Laboratories.
About the Center for Lawful Access and Abuse Deterrence
The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) is a national coalition of health care providers, law enforcement, community organizations, and businesses wor
Copyright©2012 PR Newswire.
All rights reserved